Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. by Pasina, L. et al.
European Journal of Internal Medicine 22 (2011) 205–210
Contents lists available at ScienceDirect
European Journal of Internal Medicine
j ourna l homepage: www.e lsev ie r.com/ locate /e j imOriginal article
Prevalence and appropriateness of drug prescriptions for peptic ulcer and
gastro-esophageal reﬂux disease in a cohort of hospitalized elderly
L. Pasina a,⁎, A. Nobili a, M. Tettamanti a, F. Salerno b, S. Corrao c, A. Marengoni d, A. Iorio e,
M. Marcucci e, P.M. Mannucci f
and on behalf of REPOSI Investigators 1
a Mario Negri Institute for Pharmacological Research, Milan, Italy
b Internal Medicine I, Policlinico IRCCS San Donato, University of Milan, Italy
c Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Italy
d Geriatric Unit, Spedali Civili, Department of Medical and Surgery Sciences, University of Brescia, Italy
e Department of Internal Medicine, University of Perugia, Italy
f Scientiﬁc Direction, IRCCS Maggiore Hospital Foundation, Milan, Italy⁎ Corresponding author. Laboratory for Quality Asse
and Services, Drug Information Service for the Elder
acologiche “Mario Negri”, Via Giuseppe La Masa, 19, 20
39014 579; fax: +39 02 39001916.
E-mail address: luca.pasina@marionegri.it (L. Pasina
1 REPOSI denotes Registry of Polytherapies SIMI
Interna).
0953-6205/$ – see front matter © 2010 European Fede
doi:10.1016/j.ejim.2010.11.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 September 2010
Received in revised form 23 November 2010
Accepted 23 November 2010
Available online 21 December 2010
Keywords:
Proton pump inhibitors
Appropriateness
Elderly
Background: Proton pump inhibitors (PPI) are among the most commonly prescribed medicines and their
overuse is widespread in both primary and secondary care. Inappropriate prescription is of particular concern
among elderly patients, who have often multiple comorbidities and need many drugs.
Methods: We evaluate the appropriateness of drugs for peptic ulcer or gastro-esophageal reﬂux disease
(GERD) in a sample of elderly patients (65 years old or older) at admission and discharge in 38 internal
medicine wards between January 2008 and December 2008, according to the presence of speciﬁc conditions
or gastro-toxic drug combinations.
Results: Among 1155 patients eligible for the analysis, 466 (40.3%) were treated with drugs for GERD or peptic
ulcer were at hospital admission and 647 (56.0%) at discharge; 62.4% of patients receiving a drug for peptic
ulcer or GERD at admission and 63.2% at discharge were inappropriately treated. Among these, the number of
other drugs prescribed was associated with greater use of drugs for peptic ulcer or GERD, even after
adjustment for age, sex and number of diagnoses at admission (OR 95% CI=1.26 (1.18–1.34), p=.0001) or
discharge (OR 95% CI=1.11 (1.05–1.18), p=0.0003).
Conclusions: Prevalence of inappropriate prescription of drugs for peptic ulcer or GERD remained almost the
same at admission and discharge. Inappropriate use of these drugs is related to the concomitant use of other
drugs. Careful assessment of clinical conditions and stricter adherence to evidence-based guidelines are
essential for a rational and cost-effective use of drugs for peptic ulcer or GERD.
© 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Background
Drugs for peptic ulcer or gastro-esophageal reﬂux disease (GERD),
especially proton pump inhibitors (PPI), are among the most
commonly prescribed medicines. PPI overuse is widespread in both
primary and secondary care with great implications on drug costs in
the industrialized world [1]; in Italy it accounts for about 7% of gross
pharmaceutical expenditure [2]. PPI certainly offer an improvement inssment of Geriatric Therapies
ly, Istituto di Ricerche Farm-
156 Milano, Italy. Tel.: +39 02
).
(Società Italiana di Medicina
ration of Internal Medicine. Publishthe treatment of common and important gastrointestinal diseases.
They are effective in the cure or prevention of peptic acid disorders
and in the management of GERD, esophagitis, gastric ulcer, bleeding
peptic ulcer, eradication of Helicobacter pylori, dyspepsia, Zollinger–
Ellison syndrome and prevention of gastrointestinal (GI) toxicity
induced by non-steroidal anti-inﬂammatory drugs (NSAID).
However, some studies have suggested that between 25% and 81%
of patients taking PPI had no appropriate indication and inmany cases
physicians fail to provide speciﬁc instructions about how long to
continue treatment [3–11]. PPI are frequently used in patients who do
not meet the criteria for appropriate use or for non-evidence-based
indications where less powerful, cheaper agents would be effective for
the treatment of symptoms. Although there is evidence about
superiority of the PPI over H2 receptor antagonists and others drugs
for the treatment of GERD or peptic ulcer, thanks to their stronger and
longer action, other drugs could often be an effective and safe
alternative for many patients [12–14].ed by Elsevier B.V. All rights reserved.
Box 1
Rules of AIFA for gastroprotection with PPIs and misoprostol
Rules of the AIFA allow the prescription of PPIs or misoprostol
for gastroprotection in the case that a patient chronically treated
with NSAIDs or ASA has concomitantly the presence of history
or active peptic ulcer; or concomitant therapy with an antic-
oagulant agents or corticosteroids; or advanced age (not
specified if older than 65 or 75). Rules underline that advanced
age or anticoagulant therapy is not a criteria to treat all elderly
with gastropotector, but must be considered a factor suggestive
of populations at increased risk and not a recommendation.
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elderly patients, who normally have multiple comorbidities, take
many drugs and are at higher risk of adverse drug reactions [15–17].
Although generally well tolerated, PPI can cause serious adverse
reactions. Their short-term use has been associated with infections
such as community-acquired pneumonia [18–21] or Clostridium
difﬁcile diarrhea [22,24] due to low gastric acidity, and with a loss of
efﬁcacy of clopidogrel as a result of drug interaction [25–30]. Long-
term use has been related to increases in hip fractures [31–33],
delayed diagnosis of gastric cancer and increased risk of all-cause
mortality [34,35].
The aims of the present analysis, in the cohort of elderly patients
enrolled in the REPOSI study, were to evaluate the rate of prescrip-
tions of drugs for peptic ulcer or GERD at admission and discharge in a
sample of Italian internal medicine wards and to analyze the
appropriateness of use in relation to evidence-based indications.
2. Methods
2.1. Data collection
The Registro Politerapie SIMI (REPOSI) study is a collaborative,
independent, voluntary effort by the Italian Society of Internal
Medicine (SIMI) and the Mario Negri Institute for Pharmacological
Research, run between January 2008 and December 2008 in a sample
of 38 internal medicine wards in various Italian regions. This
multicenter collaborative longitudinal study was designed to create
a network of internal medicine and geriatric wards in order to collect
information on a sample of elderly in-patients with multiple diseases,
needing polytherapy, to describe the prevalence of these diseases and
the treatments, to analyze the predictors, and to record the main
clinical outcomes at hospital discharge.
To ensure an unselected population of elderly patients admitted to
internal medicine wards, during four-week period threemonths apart
(one in February, one in June, one in September, and one in December
2008) the ﬁrst ten patients admitted to the wards participating in the
study were consecutively recruited if they were 65 years old or older.
For this observational study, conducted on anonymous patient
records, approval by the Ethics Committee was not required.
Participation in the study was voluntary and all the patients gave
signed informed consent. For each patient, a standardized web-based
case report formwas completed by the attending physician, including
socio-demographic factors, clinical parameters, diagnoses and treat-
ments at hospital admission and discharge, clinical events while in
hospital, and outcome. All the data were collected and checked by a
central monitor at the Mario Negri Institute for Pharmacological
Research, Milan.
2.2. Diseases and drug appropriateness
Diagnoses examined were recorded at hospital admission and
discharge and conﬁrmed by caregivers on the basis of clinical
examination, anamnesis, laboratory and instrumental data. Diagnoses
were made using standardized criteria. The International Classiﬁca-
tion of Diseases-Ninth Revision (ICD-9) (World Health Organization,
1987) [36] was used for classifying all diseases. Drugs were recorded
according to the Anatomical Therapeutic Chemical classiﬁcation
system (ATC) (WHO 1990) [37].
The appropriateness of drug prescriptions for peptic ulcer and
GERD (ATC classiﬁcation code: A02B) was assessed retrospectively
taking into account the presence of a pathological condition requiring
their use or the presence of gastro-toxic drug combinations [6,38,39],
which we deﬁned as concomitant therapy with NSAIDs or low doses
of acetylsalicylic acid (ASA) together with oral corticosteroids or
antithrombotic therapy. Criteria used to identify gastro-toxic drug
combinations are in accordance with the stronger evidence-basedindications [6], which reﬂect the rules [7] of the Agenzia Italiana del
Farmaco (AIFA, the Italian Drug Agency) for gastroprotection with
PPIs and misoprostol in order to prevent gastrointestinal toxicity in
patients using gastro-toxic drug combinations (Box 1).
The pathological conditions in which we assessed the appropri-
ateness of A02B drug use were classiﬁed on the basis of the diagnosis
at hospital admission and/or at discharge, with the speciﬁc ICD-9
codes. We considered all patients with diseases of the esophagus,
stomach, and duodenum (ICD-9 codes from 530 to 538 and 578), or
with H. pylori infection (ICD-9 code 041.86).
Drugs for peptic ulcer or GERDwere identiﬁed from the list of drugs
administered at admission and discharge according to the ATC
classiﬁcation (the third level code A02B). Similarly, gastro-toxic drug
combinations were identiﬁed according to the second, third, fourth or
ﬁfth level of the ATC code as follows: H02 for corticosteroids, M01A and
N02BA for non-steroidal anti-inﬂammatory drugs, B01A, B01AB, and
B01AC for oral antithrombotic drugs other than ASA, and B01AC06 and
for ASA.M01Bwere not included in analysis because nodrug is available
in Italy with this code. All N02BA drugs recorded at hospital admission
corresponded to acetylsalicylic acid 100 mg prescribed for cardiopro-
tection on the basis of clinical indication recorded. So these medication
were coded as B01AC06. In accordance with this criteria, patients
appropriately treated with drug for peptic ulcer and GERD were those
with gastrointestinal diseases, such as ulcer, esophageal diseases,
gastritis, duodenitis or Helicobacter infection or those receiving a
gastro-toxic drug combinations, such as concomitant therapy with
NSAIDs or low doses of acetylsalicylic acid (ASA), together with oral
corticosteroids or antithrombotic therapy.
3. Statistical analysis
Conﬁdence intervals on percentages of drug use were computed
using score conﬁdence intervals.
Statistical signiﬁcance of differences in possible predictors for
inappropriate prescription of drugs for the treatment of GERD or
peptic ulcer was evaluated using logistic regression, at the univariate
and multivariate levels. Analyses were done with JMP, v. 8.0.2 (SAS
Institute Inc.). Multivariate analyses were corrected for age, sex,
number of drugs and number of diagnoses.
4. Results
In all 38 departments of internal medicine and geriatric wards
participated in the REPOSI study and recruited 1332 patients; 111
were excluded because of lack of discharge information (they were
transferred to another hospital ward not participating in the study)
and 66 because they died inhospital. Therefore 1155 patients were
eligible for this analysis.
Drugs for GERD or peptic ulcer were given to 466 patients (40.3%)
at admission and 647 (56.0%) at discharge. Themean number of drugs
used and diagnoses made were higher in patients given drugs for
peptic ulcer or GERD than in untreated patients (Table 1). PPI were the
Table 1
Main characteristics of patients recruited for the analyses.
At admission
(n=1155)
At discharge
(n=1155)
Treated
with A02Ba
Not treated
with A02B
Treated
with A02B
Not treated
with A02B
Total 466 689 647 508
Patients with disease or
gastro-toxic
combinations (%)
175 (37.6) 59 (8.6) 238 (36.8) 41 (8.1)
Age, years (mean±SD) 79.2±7.7 79.2±7.5 79.1±7.7 79.3±7.4
Women (%) 55.2 52.7 53.0 54.5
Drugs, no (mean±SD)b 5.4±2.7 3.9±2.4 5.8±2.9 4.9±2.4
Diagnoses, No (mean±SD) 4.9±2.4 3.8±2.2 6.3±2.5 5.5±2.4
a Drugs for peptic ulcer or gastro-esophageal reﬂux disease.
b Excluding the drugs for peptic ulcer or GERD.
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about 95.3% of prescriptions at admission and 95.5% at discharge.
Lansoprazole and omeprazole were the main active principles
prescribed (Table 2).
At admission 291 patients (62.4% of those receiving a drug for
peptic ulcer or GERD) and 409 at discharge (63.2%) were treated even
though they had no speciﬁc pathology or gastro-toxic drug combina-
tions that could justify the use of these drugs. Furthermore, 227
patients (78.0%; 95% CI, 72.9%–82.4%) received a drug for peptic ulcer
or GERD inappropriately at both admission and discharge. Only in 36
cases (12.4%; 95% CI, 9.1%–16.7%) were these drugs appropriately
withdrawn at hospital discharge. At admission 59 patients (5.1%; 95%
CI, 4.0%–6.5%) with gastrointestinal diseases or receiving a gastro-
toxic drug combinations and 41 (3.6%;95% CI, 2.6%–4.8%) at discharge
were inappropriately not treated with a drug for peptic ulcer or GERD.
Among patients inappropriately not treated ad admission 27 (48.5%;
95% CI, 33.7%–58.3%) received the treatment at discharge. Sex and
mean age were not different for patients who received these drugs
appropriately or inappropriately at either admission or discharge. The
mean numbers of drugs prescribed were higher among patients with
inappropriate prescription at admission (5.4±2.7 and 5.1±2.8) and
discharge (5.7±2.8 and 5.4±2.8). However the mean number of
diagnoses was higher in patients treated appropriately than inappro-
priately at admission (4.9±2.2 and 4.3±2.3) and discharge (6.2±2.4
and 5.9±2.4). In addition, among patients appropriately not treated
at admission with a drug for peptic ulcer or GERD, the drug was
prescribed at discharge to 149 (23.3%, 95% CI, 20.2%–26.7%), although
it did not need to be continued.
Among appropriately treated patients the main gastrointestinal
diseases associated with prescriptions at hospital admission or
discharge are reported in Table 3. Gastro-toxic drug combinations
were the second cause of prescription. Low doses of ASA with another
antithrombotic drug was the combination most frequently prescribedTable 2
Number of patients treated with active principles for peptic ulcer or GERD at admission
and discharge.
Antisecretory
drug
At admission
(n=466)
At discharge
(n=647)
Number
of patients
% (95% CI) Number
of patients
% (95% CI)
Lansoprazole 177 38.0 (33.7–42.5) 238 36.8 (33.2–40.6)
Omeprazole 138 29.6 (25.6–33.9) 197 30.4 (27.0–34.1)
Esomeprazole 58 12.4 (9.8–15.8) 68 10.5 (8.4–13.1)
Rabeprazole 43 9.2 (6.9–12.2) 88 13.6 (11.2–16.5)
Pantoprazole 38 8.2 (6.0–11.0) 44 6.8 (5.1–9.0)
Ranitidine 10 2.1 (1.2–3.9) 9 1.4 (0.7–2.6)
Alginic acid 7 1.5 (0.7–3.1) 9 1.4 (0.7–2.6)
Sucralfate 5 1.1 (0.5–2.5) 10 1.5 (0.8–2.8)
Misoprostol 0 0 1 0.2 (0–0.9)(45.5% and 54.0%), followed by low doses of ASA and corticosteroids.
Drugs for peptic ulcer or GERD in patients with inappropriate
prescriptionswere taken for amedianof 436 days, before the admission.
Comparing the characteristics of patients inappropriately receiving a
drug for peptic ulcer or GERD with those appropriately not treated, the
mean number of drugs was related to greater use of drugs for peptic
ulcer or GERD in univariate analysis and also after adjustment for age,
sex and number of diagnoses at either admission (OR 95%CI=1.26
(1.18–1.34), p=.0001) and discharge (OR 95%CI=1.11 (1.05–1.18),
p=0.0003). Themeannumber of diagnoseswas onlyweakly associated
with use of these drugs, and in multivariate analyses the results did not
reach statistical signiﬁcance (Table 4).
5. Discussion
This analyses shows mainly the high prevalence of inappropriate
prescription of drugs for peptic ulcer or GERD, at hospital admission
and discharge. Hospitalization is associated with rise in the rate of use
of these drugs: at admission 40% of patients were taking one of these
drugs, but 56% at discharge. Although these medications should be
prescribed in accordance with evidence-based guidelines in order to
keep down unnecessary costs and prevent adverse drug reactions,
which are a particular concern in the elderly, among patients
prescribed drugs for peptic ulcer or GERD, 66% at admission and
64% at discharge did not have any appropriate indication. Though the
prevalence of inappropriate use of drugs for peptic ulcer or GERD was
not different at admission and discharge, it is important to underline
that at discharge more patients were receiving these drugs inappro-
priately (304 at admission and 415 at discharge). Moreover, 23% of
patients who were appropriately not receiving these drugs at
admission, were nevertheless prescribed these at discharge even
without a speciﬁc indication. Furthermore prevalence of patients
inappropriately not treated at admission or discharge were similar
and we don't know if they were not receiving the treatment due to
drug intolerance or if they were inappropriately not treated. These
ﬁndings are comparable to studies conducted in other countries to
evaluate the licensed or unlicensed prescription of PPI. In Greece, PPI
were inappropriately prescribed to 81% of patients in a department of
internal medicine [9], in UK PPI were prescribed for unlicensed
indications in 67% of patients [40], and in Ireland this rate was nearly
63% [41]. In another Italian study, assessing the appropriateness of
acid-suppressive therapy in a cohort of hospitalized patients and its
fallout on prescriptions in general practice, anti-secretory drugs,
especially PPI, were not indicated in 41.5% of patients admitted to a
department of internal medicine, acceptable in 6.5% and indicated in
50.1%; the main reason for inappropriate use was prophylaxis in low-
risk patients (64.8%) [42]. In Australia, according to two studies, PPIs
were appropriately prescribed only in 37.1% or 31% of cases [5,43].
Similarly in Spain, the prescription of PPIs was reported to be
appropriate in 36.4% or 28% of patients [44,45].
Compared to other study, the main strength of our ﬁndings is that
inappropriate use of these drugs is signiﬁcantly related to the mean
number of concomitant drug used, independently by the prescription
of gastro toxic drug combinations. However a large number of co-
administered drugs should not necessarily indicated the need for
gastroprotective agents; closer evaluation of the underlying clinical
conditions and prescribing patterns more closely linked to evidence-
based guidelines and national recommendations are therefore
essential for a rational, cost-effective approach. For patients in the
hospital physicians should consider the possibility of withdrawing
drugs for peptic ulcer or GERD if there is no pathological condition
warranting their use, and in patients not taking gastro-toxic drug
combinations. Patients should be given speciﬁc recommendations
about how long to continue taking the drugs in order to avoid
unnecessary, undeﬁned prolongation of treatment. In our study, with
a median time of 18 months of drug usage by patients with an
Table 3
Prevalence of gastrointestinal diseases and gastro-toxic drug combinations at admission and discharge among patient who received an appropriate drug for GERD or peptic ulcer.
Diagnoses At admission
(n=175)
At discharge
(n=238)
Number of patients % (95% CI) Number of patients % (95% CI)
Gastrojejunal ulcer 107 61.1 (53.8–68.1) 137 57.6 (51.2–63.7)
Gastro-toxic drug combinations 33 18.6 (13.8–25.3) 63 26.5 (21.3–32.4)
Esophageal disease 25 14.3 (9.9–20.2) 36 15.1 (11.1–20.2)
Gastrointestinal haemorrhage 18 10.3 (6.6–15.7) 7 2.9 (1.4–5.9)
Gastritis and duodenitis 5 2.9 (1.2–6.5) 4 1.7 (0.7–4.2)
Gastric ulcer 5 2.9 (1.2–6.5) 7 2.9 (1.4–5.9)
Duodenal ulcer 3 1.7 (0.6–4.9) 7 2.9 (1.4–5.9)
Peptic ulcer, site unspeciﬁed 2 1.1 (0.3–4.1) 1 0.4 (0.1–2.3)
Disorders of stomach function 1 0.6 (0.1–3.2) 4 1.7 (0.7–4.2)
Helicobacter pylori infection 1 0.6 (0.1–3.2) 0 0
Prevalence of gastro-toxic drug combinations
Admission
(n=33)
Discharge
(n=63)
Number of patients % (95% CI) Number of patients % (95% CI)
ASA with other antithrombotic drugs 15 45.5 (29.8–62.0) 34 54.0 (41.8–65.7)
ASA with corticosteroids 13 39.4 (24.7–56.3) 24 38.1 (27.1–50.4)
NSAIDs with corticosteroids 4 12.1 (4.8–27.3) 6 9.5(4.4–19.3)
NSAIDs with antithrombotic other than ASA 1 3.0 (0.5–15.3) 3 4.8 (1.6–13.1)
NSAIDs with ASA 1 3.0 (0.5–15.3) 1 1.6 (0.2–8.5)
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had had diseases requiring drugs for peptic ulcer or GERD prescrip-
tions were simply repeated although the disease was no longer
present. For hospital in-patients the caregiver plays an essential role
for rational and appropriate use of these drugs, discouraging
prescription in patients with no symptoms or evidence-based
indications. Physicians should recall the authorized indications and
recommendations for licensed use of these drugs. They should
constantly reassess drug therapy, considering suspending drugs in
patients with no speciﬁc diseases, symptoms or gastro-toxic drug
combinations. We also noted an unjustiﬁed increase in the use of
gastroprotectors in hospital, which could raise the risk of drug adverse
reactions and the cost for the NHS. Although lansoprazole and
omeprazole, the main PPI prescribed, are available as generic drugs in
Italy and are the cheapest PPI on the market, using these drugs for
unlicensed or inappropriate indications is an unjustiﬁed cost. We also
found that elderly patients taking multiple drugs seemed to be moreTable 4
Main characteristics of patients inappropriately receiving a drug for peptic ulcer or GERD at a
(OR) for inappropriate prescription.
At admission
(n=994)
Prescription of A02Ba Inappropriately treated
with A02B
Appro
with A
Total 291 630
Age, yrs (mean±SD) 78.9±7.9 79.2±
Women (%) 54.3 52.9
Number of different drugs (mean±SDb) 5.4±2.7 3.9±2
Number of different diagnoses (mean±SD) 4.3±2.3 3.8±2
OR (95% CI) p
Univariate analyses
Number of drugs 1.26 (1.19–1.33) b.0001
Number of diagnoses 1.11 (1.04–1.18) 0.001
Multivariate analysesc
Number of drugs 1.26 (1.18–1.34) b.0001
Number of diagnoses 0.99 (0.93–1.07) 0.84
a Drugs for peptic ulcer or gastro-esophageal reﬂux disease.
b Excluding the drugs for peptic ulcer or GERD.
c Results were corrected for age, sex, number of drugs and number of diagnoses.likely to be inappropriately treated with a drug for peptic ulcer or
GERD. The need for a large number of drugs without speciﬁc gastro-
toxic combinations is not an evidence-based indication, and does not
justify the use of a gastroprotective agent. The length of hospital stay
was also not associated to a higher probability of receiving these
drugs, in both, the univariate and multivariate model.
Patients included in the study are a representative, unselected
sample of elderly in-patients inmedicinewards in Italy and our analysis
reﬂects the prescribing habits for the drugs considered. The major limit
of the study is that information about drug prescriptions at admission
were obtained directly from patients or relatives, so real drug use and
duration of the therapy may be under-estimated compared to
information at discharge, which was collected directly by the persons
monitoring this study. This difference in the accuracy of data collection
may have contributed to the difference in drug consumption between
admission and discharge. Another limit is that we have no follow-up
after discharge, whereas it would be useful to evaluate whether or notdmission and discharge compared to patients appropriately not treated, and odds ratio
At discharge
(n=923)
priately not treated
02B
Inappropriately treated
with A02B
Appropriately not treated
with A02B
415 469
7.4 79.4±7.8 79.4±7.4
55.5 55.7
.4 5.7±2.8 4.9±2.4
.2 5.9±2.4 5.4±2.4
OR (95% CI) p
1.13 (1.07–1.19) b.0001
1.09 (1.03–1.15) 0.003
1.11 (1.05–1.18) 0.0003
1.04 (0.97–1.10) 0.28
209L. Pasina et al. / European Journal of Internal Medicine 22 (2011) 205–210overuse of drugs for peptic ulcer or GERD in the elderly in hospital is
then related to over-prescription in general practice.
Learning points
• In many cases patients taking PPI had no appropriate indication and
physicians fail to provide speciﬁc instructions about how long to
continue treatment.
• Inappropriate use of PPI is signiﬁcantly related to the mean number
of concomitant drug used, independently by the prescription of
gastro toxic drug combinations.
• Closer evaluation of the underlying clinical conditions and prescrib-
ing patterns more closely linked to evidence-based guidelines and
national recommendations are essential for a rational, cost-effective
approach.
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